rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Viatris Inc.

VTRS · Nasdaq

Health CarePharmaceuticalsLeading

VTRS stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 15.9% above that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
52 in a row
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$4,442
Insider sales, 12 months
$2.2M
Officials’ trades on record
25

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.5M$0$459KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

25 disclosed lines: House 19, Senate 3, executive 3; 16 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k18 Nov 2025filed 15 Dec 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08sold$1k–$15k8 Apr 2025filed 8 May 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k31 Mar 2025filed 7 Apr 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08bought$1k–$15k25 Feb 2025filed 27 Mar 2025
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k10 Apr 2023filed 19 May 2023
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k6 Mar 2023filed 17 Apr 2023
Daniel S. Goldman House: U.S. House ClerkNY10bought$1k–$15k31 Jan 2023filed 24 Feb 2023
Tommy Tuberville Senate: U.S. Senate eFDSenatorsold$1k–$15k1 Aug 2022filed 15 Sep 2022
Earl Blumenauer House: U.S. House ClerkOR03sold$1k–$15k14 Mar 2022filed 1 Apr 2022
Earl Blumenauer House: U.S. House ClerkOR03bought$1k–$15k24 Feb 2022filed 1 Apr 2022
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k13 Jan 2022filed 14 Feb 2022
Debbie Dingell House: U.S. House ClerkMI12sold$1k–$15k18 Jun 2021filed 29 Jun 2021

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 1
WhoDidSharesTraded
Paul CampbellOfficersold50,076at $16.1725 Jun 2026filed 26 Jun 2026
Paul CampbellOfficersold21,350at $13.2823 Mar 2026filed 24 Mar 2026
David S. SimmonsDirectorbought213at $10.433 Nov 2025filed 10 Mar 2026
David S. SimmonsDirectorbought286at $10.4227 Aug 2025filed 10 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

David S. Simmons Company insiderDirector · last 30 Sep 20262 · 0
Leo Frans Groothuis Company insiderDirector · last 30 Sep 20260 · 0
Andrew Enrietti Company insiderOfficer · last 15 Aug 20260 · 0
Paul Campbell Company insiderOfficer · last 25 Jun 20260 · 4
Corinne Le Goff Company insiderChief Commercial Officer · last 15 Apr 20260 · 1
Coelho Rogerio Vivaldi Company insiderDirector · last 6 Mar 20260 · 0
Dillon JoEllen Lyons Company insiderDirector · last 6 Mar 20260 · 1
Elisha W. Finney Company insiderDirector · last 6 Mar 20260 · 0
Frank A. Damelio Company insiderDirector · last 6 Mar 20260 · 0
James M. Kilts Company insiderDirector · last 6 Mar 20261 · 0
Mark W. Parrish Company insiderDirector · last 6 Mar 20260 · 0
Matthew Joseph Maletta Company insiderChief Legal Officer · last 6 Mar 20260 · 0

Same industry

ABBV AbbVieLeading+20%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202535.1%
Operating profit marginFY 2025 · to 31 Dec 2025-18.6%
Free cash flow marginFY 2025 · to 31 Dec 202513.5%
Return on capital employedFY 2025 · to 31 Dec 2025-8.8%
Debt to equityFY 2025 · to 31 Dec 20250.98×
Interest coverFY 2025 · to 31 Dec 2025-5.65×
Dividend growthFY 2025 · to 31 Dec 2025300%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.3B
Free cash flowFY 2025 · to 31 Dec 2025$1.9B

Analyst forecasts

No analyst forecasts yet.